Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: recombinant Bifidobacterium anticancer therapeutics - Anaeropharma Science

Drug Profile

Research programme: recombinant Bifidobacterium anticancer therapeutics - Anaeropharma Science

Alternative Names: anti-4-1BB scFV - Anaeropharma Science; Anti-CTLA4 scfv - Anaeropharma Science; Anti-PD-1 and Anti-CTLA4 scfv - Anaeropharma Science; APS-001; B. longum producing anti-4-1BB scFV - Anaeropharma Science; BEST-CD; BifidobactErial Selective Targeting-Cytosine Deaminase therapy; FGF2 producing B. longum - Anaeropharma Science

Latest Information Update: 26 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Anaeropharma Science
  • Developer Anaeropharma Science; Eisai Co Ltd
  • Class Anti-ischaemics; Antineoplastics; Bacteria; Gene therapies
  • Mechanism of Action CD137 antigen agonists; Cytotoxic T-lymphocyte antigen 4 inhibitors; Fibroblast growth factor replacements; Gene transference; Programmed cell death-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Peripheral arterial disorders

Most Recent Events

  • 21 Apr 2018 Preclinical data in Cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR - 2018)
  • 08 Aug 2017 Preclinical trials in Peripheral arterial disorders in Japan (IV) before August 2017 (Anaeropharma Science pipeline, August 2017)
  • 21 Dec 2015 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top